Prevalence of iodine- and thyroglobulin-negative findings in differentiated thyroid cancer - A retrospective analysis of patients treated from 1961 to 1998 in a university hospital
S. Klutmann et al., Prevalence of iodine- and thyroglobulin-negative findings in differentiated thyroid cancer - A retrospective analysis of patients treated from 1961 to 1998 in a university hospital, NUKLEARMED, 40(5), 2001, pp. 143-147
Aim: The prevalence of iodine- and thyroglobulin-negative findings was eval
uated in all patients with differentiated thyroid cancer (DTC) treated from
1961 until 1998 at the Department of Nuclear Medicine, University Hospital
Hamburg-Eppendorf. Methods: A total of 490 patients with papillary thyroid
cancer (PCA) and 242 patients with follicular thyroid cancer (FCA) were an
alyzed retrospectively. Patients were divided into four groups: 1: no recur
rence, 2: recurrent disease, 3: primary metastatic/progressive disease and
4: inconclusive follow-up. Results of iodine scan, serum-TG, and additional
imaging modalities as well as histology were compared in all patients. Res
ults: 21/490 (4,3%) of patients with PCA and 16/242 (6,6%) with FCA suffere
d from recurrent disease. 62/490 (12,7%) of patients with PCA and 59/242 (2
4,4%) with FCA had primary metastatic/progressive disease. 12/21 patients w
ith PCA and 12/16 with FCA showing up with recurrent disease had a negative
iodinescan. 11/21 of patients with PCA and 4/16 with FCA and tumor recurre
nce had negative serum-TG levels. 14/62 patients with PCA and 14/59 with FC
A presenting with primary metastatic/progressive disease had negative iodin
escan. 14/62 patients with PCA and 6/59 with FCA had negative serum-TG. Con
clusion: The prevalence of iodine-negative recurrent/metastatic disease is
in accordance to the literature, whereas the prevalence of TG-negative recu
rrent/metastatic was noted higher than reported previously. Thus, the commo
nly used follow-up scheme of DTC is confirmed. However, iodine scan should
be regularly performed in patients with high risk of recurrence.